AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AEON Biopharma, Inc. (AEON) on March 6, 2026. The filing discloses the appointment of a new Chief Financial Officer and the execution of employment agreements for senior financial leadership. The Company is an emerging growth company incorporated in Delaware, with its Class A Common Stock trading on NYSE American under the symbol "AEON."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and equity plan amendments.
Material Changes and Executive Appointments
On March 6, 2026, the Board of Directors appointed John Bencich as Chief Financial Officer, effective March 9, 2026, and as principal financial officer, effective April 1, 2026. Mr. Bencich brings over 25 years of experience in biotechnology finance, including prior roles as CEO of Achieve Life Sciences and CFO of Oncogenex Pharmaceuticals. Additionally, the Company formalized an employment agreement with its Chief Accounting Officer, Jennifer Sy.
Compensation and Equity Details
- John Bencich (CFO):
- Base Salary: $450,000 per year.
- Target Annual Cash Bonus: 40% of base salary.
- Equity Grant: 754,717 Restricted Stock Units (RSUs) vesting over four years (25% annually).
- Performance Equity: 235,849 Performance-Based RSUs (PSUs). Vesting is tied to regaining NYSE American listing compliance, with 25% vesting six months after compliance is achieved and the remainder vesting annually thereafter.
- Severance: Up to 12 months of salary and 100% of target bonus in the event of termination without cause or resignation for good reason surrounding a Change in Control.
- Jennifer Sy (Chief Accounting Officer):
- Base Salary: $275,000 per year (unchanged).
- Target Annual Cash Bonus: 30% of base salary.
- Severance: Up to 12 months of salary and 100% of target bonus in the event of termination without cause or resignation for good reason surrounding a Change in Control.
Equity Plan Amendment
Effective March 6, 2026, the Board amended the 2025 Employment Inducement Incentive Award Plan to reserve an additional 1,000,000 shares of Class A common stock for issuance. This amendment was adopted without stockholder approval pursuant to NYSE American rules.
Outlook and Risks
Management stated that Mr. Bencich's appointment is part of a strategic plan to strengthen executive leadership as the Company advances key regulatory and financing milestones. A specific risk highlighted in the equity structure is the Company's current status regarding NYSE American listing standards; the vesting of a significant portion of the new CFO's performance equity is contingent upon successfully regaining compliance with these standards.
Investor Verification Checklist
- Verify the Company's current compliance status with NYSE American listing standards, as this directly impacts the vesting of the new CFO's performance equity.
- Review the attached employment agreements (Exhibits 10.1 and 10.2) for specific definitions of "cause," "good reason," and "Change in Control."
- Confirm the total number of shares reserved under the 2025 Employment Inducement Incentive Award Plan following the 1,000,000 share increase.
- Monitor upcoming filings for the Company's progress on regulatory and financing milestones mentioned in the strategic plan.